Lundbeck is a Danish pharmaceutical company and is registered in the Philippines as a Representative Office of Lundbeck Export A/S.
Our vision is to become a world leader in psychiatry and neurology while our mission is to improve the quality of life for people suffering from psychiatric and neurologic disorders.
We market Brintellix (Vortioxetine), the first and only available multimodal antidepressant in the Philippines, Lexapro (Escitalopram), the proven treatment for depression and anxiety, Abixa (Memantine), the first NMDA Receptor Antagonist for moderate to severe Alzheimer's Disease, Azilect (Rasagiline), the first adjunct therapy for Parkinson's Disease and Fluanxol (Flupentixol Decanoate), a traditional antipsychotic that continues to benefit many patients, mostly in the public institutions.
We also have a number of drugs in our R&D pipeline that will be launched in the coming years. While everybody else is into diversification, we remain focused on Central Nervous System (CNS) which is believed to have the biggest debilitating disorders by year 2030.
In Asia, and especially in the Philippines, there is still a social stigma surrounding CNS disorders and therefore, an important goal for us is to consistently contribute in raising awareness of it. We do not have direct patient access; Instead, we partner with the Philippine Psychiatric Association (PPA), Philippine Neurological Association (PNA) and other medical societies in shared-care initiatives that improve the overall mental health state.
We have a focused and dedicated team that makes all these possible since we started our operations in the Philippines on 03 March 2003.